Results 51 to 60 of about 2,934 (87)

Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study. [PDF]

J Gynecol Oncol
Hu L, Li J, Du Y, Mei F, Li F.
europepmc   +1 more source

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy. [PDF]

Support Care Cancer
Harikul W, Nimmannit A, Laocharoenkeat A, Phisalprapa P, Kositamongkol C, Thongkijpreecha P, Ithimakin S.   +6 more
europepmc   +1 more source

Multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent chemoradiotherapy in Chinese patients with high-risk rectal cancer. [PDF]

Oncologist
Lui RN, Chu S, Ng DCK, Li L, Cho CCM, Hung EHY, Wong KH, Mo FKF, Wong ECH, Hui CWC, Lam DCM, Suen J, Kang W, Ho WM, Futaba K, Hon SSF, Yan K, Ng SSM, Ma BBY.   +18 more
europepmc   +1 more source

Evaluating Oxaliplatin Exposure in Adults with Advanced Colorectal Cancer: Development and Validation of Methods with Enhanced Bioanalytical Specificity and Clinical Applicability. [PDF]

Eur J Drug Metab Pharmacokinet
Ho J, Han C, McKeage MJ.
europepmc   +1 more source

Metabolomics and proteomics analyses reveal the potiental mechanisms underlying colorectal cancer and chemotherapy targets. [PDF]

BMC Cancer
Li Q, Chen Q, Chang J, Fu T, Xiao T, Chen J, Yang T.   +6 more
europepmc   +1 more source

Mitophagy and Bip-PERK-eIF2α-ATF4 Axis-Mediated ER Stress Mediate Miriplatin-Loaded Liposome's Anti-Colorectal Cancer Action. [PDF]

Cell Prolif
Zhao C, Qiu Y, Wang X, Wang M, Liu L, Zhao X, Gao Z, Shao R, Xia G, Zhao W.   +9 more
europepmc   +1 more source

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147). [PDF]

J Clin Oncol
Sinicrope FA, Segovia D, Sharma N, Alberts SR, Hardin A, Rich T, Shi Q.   +6 more
europepmc   +1 more source

Leveraging platinum-protein interactions to overcome chemoresistance. [PDF]

Nat Commun
Wang F, Braverman J, Eng G, Leylek O, Petrone NL, Honeycutt DS, Imada S, Pallares B, Zhang D, Mrosla JM, Huang CS, Griadunova AA, McCarthy WK, Goldberg JM, Hemann MT, Lippard SJ, Yilmaz ÖH.   +16 more
europepmc   +1 more source

Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. [PDF]

Int J Clin Oncol
Umemiya M, Kou K, Inayama Y, Kamei J, Yamaguchi K, Yamada Y, Itaya T, Yamamoto Y, Mandai M, Ogawa Y.   +9 more
europepmc   +1 more source

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer. [PDF]

Signal Transduct Target Ther
Chibaudel B, Dourthe LM, André T, Henriques J, Bourgeois V, Etienne PL, Desramé J, Carola E, Dupuis O, Baba-Hamed N, Auby D, Louvet C, Maillard E, Romano O, Tournigand C, Garcia-Larnicol ML, Shacham-Shmueli E, Bird BH, Ghiringhelli F, de Gramont A.   +19 more
europepmc   +1 more source